Clinical Trials Logo

CGD clinical trials

View clinical trials related to CGD.

Filter by:
  • None
  • Page 1

NCT ID: NCT05600907 Recruiting - Clinical trials for Chronic Granulomatous Disease

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Start date: January 2, 2023
Phase: Early Phase 1
Study type: Interventional

Background: Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD. Objective: To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated donor. Eligibility: People aged 4 to 65 years with CGD who require a transplant. Design: Participants will be screened. Part of the screening will help to identify the best match to a transplant donor. Participants will have a physical exam, including dental and eye exams. They will have blood and urine tests. They will have tests of their breathing and heart function. A bone marrow sample will be taken. They will have their stem cells collected. Participants will have a catheter inserted into a vein in their chest. It will remain in place for the entire period of transplant and recovery. Participants will be in the hospital 40 to 50 days for the transplant. This will include a conditioning phase, to prepare their body for the procedure, as well as the transplant and recovery phases. As part of the conditioning phase, participants will receive JSP191 through a vein for 1 hour. After discharge, participants will have follow-up visits 2 times a week for 100 days. Additional follow-up visits will continue for 5 years....

NCT ID: NCT05546775 Not yet recruiting - CGD Clinical Trials

Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease

Start date: September 20, 2022
Phase:
Study type: Observational

Immunological profile and Clinical characteristics of children diagnosed with chronic granulomatous disease

NCT ID: NCT02233036 Completed - CGD Clinical Trials

Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease

Start date: March 26, 2014
Phase:
Study type: Observational

Background: People who get chronic illnesses as children are living longer. When they turn 18, they switch from pediatric care to adult care. This can be a difficult change. Chronic Granulomatous Disease (CGD) is an inherited disease. It causes long-term, repeated infections. People with CGD are usually diagnosed when they are very young children. Researchers want to find out more about how young people with CGD handle the change to adult care. What they learn may make this easier for people with CGD in the future. Objective: - To identify what helped or hurt young adults with CGD as they went from pediatric to adult care. Eligibility: - Adults with CGD who were 18 24 years old between January 2011 and February 2014. Design: - Participants will already be enrolled in NIH studies. - Eligible people will get materials in the mail. They will get a letter with study information, an interview questionnaire, and an information sheet. - Researchers will call participants 1 week after the packets are sent. They will talk about the study and find out if the person wants to join. - An interview will be completed immediately or scheduled for the future. The interview will take about 45 minutes. The researcher will ask the participant about their disease. They will also ask about travel to NIH, being an outpatient or inpatient there, and legal documents. - Researchers may contact the subjects again by phone if they need more information at any point during the study.

NCT ID: NCT01953016 Completed - Clinical trials for Wiskott-Aldrich Syndrome

Participation in a Research Registry for Immune Disorders

Start date: September 30, 2013
Phase:
Study type: Observational

Background: - People with primary immune deficiency diseases (PIDD) have weak immune systems. This makes it hard for their bodies to fight infection. The Immune Deficiency Foundation has a network to collect data about people with PIDD. It is called the United States Immunodeficiency Network. It will help doctors and scientists better understand these disorders. The goal is to get medical data for everyone with these disorders in the U.S. and Canada. Data will be stored in a registry. Researchers can use it to study if these disorders are increasing. They can also learn how the disorders are diagnosed and treated. Objectives: - To collect data on people with primary immune deficiency disorders. Eligibility: - People who have a PIDD. Design: - Data can be added with no record of personal identity. - Data can be added with identity kept separate. This data will be linked to the registry by a code number. - Data for the registry includes: - Family history - Disease treatment - Disease characteristics - Medical history - Laboratory data